Solazyme’s Algenist Brand Wins Coveted 2014 Marie Claire Excellence in Beauty Award SOUTH SAN FRANCISCO, Calif.—January 21, 2014—Solazyme, Inc.(NASDAQ: SZYM), a renewable oil and bioproducts company, and maker of the skincare brand, Algenist®, today announced that the line has won…
Tag: East Grand
Ferry not an option as AMGEN cleans up explosion
South San Francisco, CA January 8, 2014 Firefighters were called out to what was reported to be a structure fire today at 3:27pm at local biocompany AMGEN at 1120 Veterans in the East 101 area. Dispatch upped the response to…
SSFPD Attempted Murder- UPDATE ARREST MADE
South San Francisco, CA September 23, 2013
Theravance to proceed with plan to split business
SOUTH SAN FRANCISCO, Calif. (AP) —June 17, 2013 Bloomberg Business Week Drug developer Theravance Inc. plans to split into two independent, publicly traded companies after a royalty agreement it had ironed out with Irish drugmaker Elan Corp. PLC fell through.…
VistaGen Therapeutics Inc.Advancements
VistaGen Therapeutics Presents CardioSafe 3D(TM) and LiverSafe 3D(TM) Developments at International Society of Stem Cell Research’s 11th Annual Meeting VistaGen Therapeutics Inc. VSTA | 6/17/2013 10:29:22 AM VistaGen Therapeutics Presents CardioSafe 3D(TM) and LiverSafe 3D(TM) Developments at International Society of…
City Council Agenda June 12, 2013 – Public Hearing
Public Hearing On Genentech Master Plan Changes South San Francisco, CA June 7, 2013 AGENDA CITY COUNCIL CITY OF SOUTH SAN FRANCISCOREGULAR MEETING MUNICIPAL SERVICES BUILDING COMMUNITY ROOMWEDNESDAY , JUNE 12, 2013 7:00 P.M. PEOPLE OF SOUTH SAN FRANCISCOYou…
Titan Pharmaceuticals, Inc receives response letter from FDA
TITAN PHARMACEUTICALS RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA FOR PROBUPHINE NEW DRUG APPLICATION SOUTH SAN FRANCISCO, CA, April 30, 2013 – FOR IMMEDIATE RELEASE Titan Pharmaceuticals, Inc. (OTCBB: TTNP) announced that the U.S. Food and Drug Administration (FDA) has…
Theravance to separate company into two benefits public trading
Theravance Announces Plan to Separate Late-Stage Partnered Respiratory Assets From Biopharmaceutical Operations Designed to Unlock Potential Value, Facilitate Return of Capital to Stockholders and Further Strategy of Advancing Medicines That Address Unmet Medical Needs SOUTH SAN FRANCISCO, CA — (Marketwired)…
South San Francisco Biomedical Company Awarded $60M Contract Option
Achaogen Awarded $60M Contract Option by BARDA for the Clinical Development of Plazomicin April 24, 2013 – Contract to fund Phase 3 superiority study of plazomicin in patients with carbapenem-resistant Enterobacteriaceae (CRE) infections – South San Francisco, CA, April 24,…
Monthly BioScience Forum Slated for May 22 Holiday Inn South San Francisco
“Building a Research-Based Discovery Engine in Biotech, and Why it Matters” Speaker: Austin Gurney, Ph.D. Senior Vice President, Molecular and Cellular Biology OncoMed Pharmaceuticals, Inc. Abstract: Biotechnology has revolutionized drug discovery in the nearly four decades since its founding. However…